Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo
Takes up Global Rights
- Payment to Bioniche of US$8M by Endo Pharmaceuticals -
BELLEVILLE, ON,
Endo Pharmaceuticals has also elected to exercise its option for exclusive rights to develop and market the product globally. As a result of the decision, Endo will all assume all external development expenses for the product.
"We are pleased with this decision by Endo," stated Graeme McRae, Chairman, President and CEO of Bioniche Life Sciences Inc. "We look forward to ongoing collaboration in addressing the global market opportunity for our bladder cancer product, as well as effectively completing the clinical development program and achieving product registrations in global jurisdictions."
Under the licensing agreement, Bioniche has the potential to receive a total of US$110 million in payments associated with the achievement of certain clinical, regulatory and commercial milestones. The achievement of the first milestone of US$6 million was announced by the Company in
Bioniche's patented intravesical formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed for the treatment of non-muscle-invasive bladder cancer (Urocidin(TM)) is undergoing a U.S. Food and Drug Administration (FDA) fast tracked Phase III registration study of the product for the treatment-refractory indication. Future plans to further develop Urocidin(TM) are being defined and will be disclosed by Endo.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
%SEDAR: 00013159EF
For further information: Jennifer Shea, Vice-President, Communications, Investor & Government Relations, Bioniche Life Sciences Inc., Telephone: (613) 966-8058, Cell: (613) 391-2097, [email protected]
Share this article